May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Survey of management of acquired nystagmus in the United Kingdom
Author Affiliations & Notes
  • I. Choudhuri
    Ophthalmology, Leicester Royal Infirmary, Leicester, United Kingdom
  • Footnotes
    Commercial Relationships  I. Choudhuri, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2527. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. Choudhuri; Survey of management of acquired nystagmus in the United Kingdom . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2527.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Background: Acquired nystagmus causes significant symptoms of visual reduction with oscillopsia. The management includes medical and surgical interventions but evidence for both options is sparse. Purpose: To establish the current management options used by ophthalmologists and neurologists in acquired nystagmus. Methods: A questionnaire was sent out to all ophthalmologists and neurologists in the UK. Names were obtained from the Royal College of Ophthalmologists and British Neurological Association. Information about patients seen with acquired nystagmus, treatment options and results of treatment was collected. Results: Ophthalmologists – Out of 850 questionnaires 308 ophthalmologists replied. 177 respondents saw patients with acquired nystagmus. 150 respondents saw less than 5 patients annually and 28 saw more than 5 patients annually. Medical treatments included gabapentin (6), baclofen (5) and memantine (1). Botulinum toxin was used by 2 ophthalmologists. 11 ophthalmologists treated the condition surgically, of whom 5 listed Kastenbaum’s procedure. Neurologists – 135 neurologists replied from a total of 434 questionnaires. 128 neurologists saw patients with acquired nystagmus. 20 neurologists saw less than five patients annually while 106 saw more than five. Medical treatments included baclofen (48), gabapentin (48), clonazepam (12), memantine (3), carbamazepine (5), benzhexol (1), ondansetrone (1) and buspirone (1). Botulinum toxin was used by one neurologist. Overall, symptomatic improvement with medical treatment was noted by 11 ophthalmologists and 52 neurologists. Improved vision with medical treatments was seen by 11 ophthalmologists and 44 neurologists. Several side effects were reported with different treatments. Conclusion: We report the first national survey of treatment of acquired nystagmus. It highlights the need for evidence–based knowledge on treatment of acquired nystagmus.

Keywords: nystagmus 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.